摘要
Gastric cancer,which has a high incidence and poor prognosis,remains a therapeutic challenge.Recently,neoadjuvant therapy has attracted increasing attention due to high recurrence rate and low survival rate after resection in most patients with advanced stage.Clinical trials show that neoadjuvant approaches confer a significant survival advantage for resectable locally advanced gastric cancer.The specific advantages of chemoradiotherapy compared with chemotherapy have not been clarified;optimal regimens and cycles,particularly in the preoperative setting,should be studied further;and trials aimed at determining the role of targeted and immunological therapies should be conducted.
